Carboplatin and Oral Etoposide for Cancer of Unknown Primary Site
Author Information
Author(s): E Warner, R Goel, J Chang, W Chow, S Verma, J Dancey, E Franssen, H Dulude, M Girouard, J Correia, G Gallant
Primary Institution: Toronto-Sunnybrook Regional Cancer Centre
Hypothesis
The combination of carboplatin and prolonged oral etoposide will improve efficacy and minimize toxicity in patients with cancer of unknown primary site (CUPS).
Conclusion
The combination of carboplatin with prolonged oral etoposide has moderate activity and is well tolerated, making it a reasonable choice for treating CUPS patients.
Supporting Evidence
- Response rate was 23% with responses lasting a median of 11 months.
- Median survival for all patients was 5.6 months.
- Non-haematological toxicity was mild to moderate, with some severe cases.
Takeaway
Doctors tested a new medicine combination to help cancer patients who don't know where their cancer started. It worked okay and didn't make people too sick.
Methodology
Patients received carboplatin and oral etoposide over several cycles, with evaluations for toxicity and response.
Limitations
The study had a small sample size and included patients with extensive disease, which may affect the generalizability of the results.
Participant Demographics
Median age was 62 years, with 16 males and 17 females.
Want to read the original?
Access the complete publication on the publisher's website